Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Biotechnologie

Mr. Bhaskar  Anand

Senior Vice President & Chief Accounting Officer

Vice President & Chief Accounting Officer

Mr. Michael D. Wortley

Executive Vice President and Chief Legal & Compliance Officer

Dr. Samina  Khan M.D.

Chief Medical Officer & Senior Vice President

Executive Vice President & Chief Legal Officer

Dr. Colin J. Meyer M.D.

Executive Vice President & Chief Innovation Officer

Mr. Steve  Harman

Senior Vice President & Chief HR Officer

Mr. Dakota  Gallivan

Vice President & Chief Healthcare Compliance Officer

Ms. Dawn Carter Bir

Executive Vice President & Chief Commercial Officer

Dr. W. Christian Wigley Ph.D.

Senior Vice President & Chief Scientific Officer

Mr. J. Warren Huff

Chairman & Chief Executive Officer

Ms. Elaine  Castellanos

Consultant

Chairman, Chief Executive Officer & Sec.

Mr. Manmeet Singh Soni

Chief Operating Officer, Chief Financial Officer & Pres

Název	Tržní kapitalizace
Maravai LifeSciences Holdings, Inc.	0M
Comera Life Sciences Holdings, Inc.	0M
CytoTools AG	0M
Hofseth BioCare ASA	0M
Purple Biotech Ltd.	0M
Starpharma Holdings Limited	0M

Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Seznam konkurentů

Hlavní konkurenti